PGEN
Precigen, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -30.0% ·
share flow -9.0% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 910 | $7,453 | +1 | n/a |
| Q2 2026 | 80 | +1 | 77.32M | $440.58M | +8 | −7 |
| Q1 2026 | 82 | +6 | 77.19M | $298.23M | +8 | −2 |
| Q4 2025 | 75 | -2 | 85.66M | $358.05M | n/a | −2 |
| Q3 2025 | 16 | +1 | 41.97M | $138.07M | +2 | −1 |
| Q2 2025 | 12 | +2 | 40.00M | $56.80M | +2 | n/a |
| Q1 2025 | 7 | 0 | 18.74M | $27.92M | +1 | −1 |
| Q4 2024 | 7 | -3 | 18.78M | $21.04M | n/a | −3 |
| Q3 2024 | 9 | +1 | 17.66M | $16.73M | +1 | n/a |
| Q2 2024 | 8 | n/a | 6.84M | $10.80M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 10.87M | 0.0% | $12.17M | 0.0% | Held | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.30M | +1.6% | $3.70M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 2.97M | n/a | $3.33M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 1.07M | -33.3% | $1.20M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 424.90K | -65.1% | $475,888 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 130.27K | -23.1% | $146,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 19.93K | +25.4% | $22,326 | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $362,738 | was 0.0% |
| Millennium Management | $112,762 | was 0.0% |
| Two Sigma Investments | $40,876 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 204 holders, 132.74M shares, $508.64M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 3.41K sh @ 7.23 · $24,662
Open-market sales (S)
Director · 185.00K sh · $1.38M
Officer · 15.34K sh · $115,065
Officer · 79.17K sh · $593,745
Officer · 34.66K sh · $259,935
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology